An official American thoracic society/ European respiratory society statement: Research questions in COPD

European Respiratory Review

Volumn 24, Issue 136, 2015, Pages 159-172

  Celli, Bartolome R ^b   Decramer, Marc ^b   Wedzicha, Jadwiga A ^b   Wilson, Kevin C ^a   Agustí, Alvar A ^b   Criner, Gerard J ^b   MacNee, William ^b   Make, Barry J ^b   Rennard, Stephen I ^b   Stockley, Robert A ^b   Vogelmeier, Claus ^b   Anzueto, Antonio ^b   Au, David H ^b   Barnes, Peter J ^b   Burgel, Pierre Regis ^b   Calverley, Peter M ^b   Casanova, Ciro ^b   Clini, Enrico M ^b   Cooper, Christopher B ^b   Coxson, Harvey O ^b   Dusser, Daniel J ^b   Fabbri, Leonardo M ^b   Fahy, Bonnie ^b   Ferguson, Gary T ^b   Fisher, Andrew ^b   Fletcher, Monica J ^b   Hayot, Maurice ^b   Hurst, John R ^b   Jones, Paul W ^b   Mahler, Donald A ^b   Maltais, François ^b   Mannino, David M ^b   Martinez, Fernando J ^b   Miravitlles, Marc ^b   Meek, Paula M ^b   Papi, Alberto ^b   Rabe, Klaus F ^b   Roche, Nicolas ^b   Sciurba, Frank C ^b   Sethi, Sanjay ^b   Siafakas, Nikos ^b   Sin, Don D ^b   Soriano, Joan B ^b   Stoller, James K ^b   Tashkin, Donald P ^b   Troosters, Thierry ^b   Verleden, Geert M ^b   Verschakelen, Johny ^b   Vestbo, Jorgen ^b   Walsh, John W ^b   Washko, George R ^b   Wise, Robert A ^b   Wouters, Emiel F M ^b   ZuWallack, Richard L ^b   more..

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDACATEROL; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINE GUM; NICOTINE PATCH; OXYGEN; SALMETEROL; SHORT ACTING DRUG; TIOTROPIUM BROMIDE; VARENICLINE;

ARTICLE; AVIATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; COMMUNITY BASED REHABILITATION; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; COUNSELING; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; ELECTRONIC CIGARETTE; ERGOMETRY; HUMAN; HYPOXEMIA; INTEGRATIVE MEDICINE; LUNG RESECTION; LUNG TRANSPLANTATION; MEDICAL RESEARCH; MEDICAL SOCIETY; NONINVASIVE VENTILATION; NUTRITION; OXYGEN THERAPY; PATHOPHYSIOLOGY; PHENOTYPE; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PROFESSIONAL KNOWLEDGE; PROGNOSIS; PULMONARY REHABILITATION; RISK ASSESSMENT; SMOKING CESSATION; SPIROMETRY; TERMINAL CARE; THORAX RADIOGRAPHY; TOBACCO DEPENDENCE; LUNG; LUNG FUNCTION TEST; PATHOLOGY; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; RISK REDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

BIOMEDICAL RESEARCH; COMORBIDITY; CONSENSUS; HUMANS; LUNG; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; RISK FACTORS; RISK REDUCTION BEHAVIOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84930419573     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.00000315     Document Type: Article

References (121)

1. 1 Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–946.
2. 2 Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347–365.
3. 3 O’Reilly J, Jones MM, Parnham J, et al. Management of stable chronic obstructive pulmonary disease in primary and secondary care: Summary of updated NICE guidance. BMJ 2010; 340: c3134.
4. 4 Rostron BL, Chang CM, Pechacek TF. Estimation of cigarette smoking-attributable morbidity in the United States. JAMA Intern Med 2014; 174: 1922–1928.
5. 5 Jones P, Miravitlles M, van der Molen T, et al. Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis 2012; 7: 697–709.
6. 6 Oga T, Nishimura K, Tsukino M, et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: Role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167: 544–549.
7. 7 Coxson HO, Lam S. Quantitative assessment of the airway wall using computed tomography and optical coherence tomography. Proc Am Thorac Soc 2009; 6: 439–443.
8. 8 Copley SJ, Wells AU, Müller NL, et al. Thin-section CT in obstructive pulmonary disease: Discriminatory value. Radiology 2002; 223: 812–819.
9. 9 Coxson HO, Mayo J, Lam S, et al. New and current clinical imaging techniques to study chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 588–597.
10. 10 Barr RG, Berkowitz EA, Bigazzi F, et al. A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD 2012; 9: 151–159.
11. 11 Galbán CJ, Han MK, Boes JL, et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 2012; 18: 1711–1715.
12. 12 Christe A, Charimo-Torrente J, Roychoudhury K, et al. Accuracy of low-dose computed tomography (CT) for detecting and characterizing the most common CT-patterns of pulmonary disease. Eur J Radiol 2013; 82: e142–e150.
13. 13 Castaldi PJ, San José Estépar R, Mendoza CS, et al. Distinct quantitative computed tomography emphysema patterns are associated with physiology and function in smokers. Am J Respir Crit Care Med 2013; 188: 1083–1090.
14. 14 Coxson HO, Leipsic J, Parraga G, et al. Using pulmonary imaging to move COPD beyond FEV1. Am J Respir Crit Care Med 2014; 190: 135–144.
15. 15 Hardie JA, Buist AS, Vollmer WM, et al. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002; 20: 1117–1122.
16. 16 Cerveri I, Corsico AG, Accordini S, et al. Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: A longitudinal evaluation of clinical and functional outcomes. Thorax 2008;
17. 17 Bhatt SP, Sieren JC, Dransfield MT, et al. Comparison of spirometric thresholds in diagnosing smoking-related airflow obstruction. Thorax 2014; 69: 409–414.
18. 18 Carlsson AC, Wändell P, Ösby U, et al. High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden – a challenge for public health. BMC Public Health 2013; 13: 670–678.
19. 19 Bridevaux PO, Gerbase MW, Probst-Hensch NM, et al. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax 2008; 63: 768–774.
20. 20 U.S. Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 148: 529–534.
21. 21 Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med 1997; 127: 1072–1079.
22. 22 Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115: 635–641.
23. 23 Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000; 320: 1297–1303.
24. 24 Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000; 117: 662–671.
25. 25 Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 14–20.
26. 26 Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: Update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012; 185: 435–452.
27. 27 Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1791–1797.
28. 28 Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856–1861.
29. 29 Mahler DA, Ward J, Waterman LA, et al. Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest 2009; 136: 1473–1479.
30. 30 Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434–1440.
31. 31 Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005–1012.
32. 32 Cote CG, Pinto-Plata VM, Marin JM, et al. The modified BODE index: Validation with mortality in COPD. Eur Respir J 2008; 32: 1269–1274.
33. 33 Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, et al. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med 2009; 103: 692–699.
34. 34 Marin JM, Alfageme I, Almagro P, et al. Multicomponent indices to predict survival in COPD: The COCOMICS study. Eur Respir J 2013; 42: 323–332.
35. 35 Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185: 1065–1072.
36. 36 Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: The updated BODE index and the ADO index. Lancet 2009; 374: 704–711.
37. 37 Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: The DOSE index. Am J Respir Crit Care Med 2009; 180: 1189–1195.
38. 38 Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155–161.
39. 39 Almagro P, Soriano JB, Cabrera FJ, et al. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: The CODEX index. Chest 2014; 145: 972–980.
40. 40 Agustí A, Barberà JA, Wouters EFM, et al. Lungs, bone marrow, and adipose tissue. A network approach to the pathobiology of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188: 1396–1406.
41. 41 Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852.
42. 42 Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: 1184–1192.
43. 43 Freimer N, Sabatti C. The human phenome project. Nat Genet 2003; 34: 15–21.
44. 44 Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598–604.
45. 45 Drazen JM, Fabbri LM. Ageing and multimorbidity. Eur Respir J 2014; 44: 557.
46. 46 Faner R, Cruz T, López-Giraldo A, et al. Network medicine, multimorbidity and the lung in the elderly. Eur Respir J 2014; 44: 775–788.
47. 47 Divo MJ, Martinez CH, Mannino DM. Ageing and the epidemiology of multimorbidity. Eur Respir J 2014; 44: 1055–1068.
48. 48 Patel AR, Donaldson GC, Mackay AJ, et al. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest 2012; 141: 851–857.
49. 49 Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962–969.
50. 50 de Torres JP, Marín JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease –incidence and predicting factors. Am J Respir Crit Care Med 2011; 184: 913–919.
51. 51 Wilson DO, Leader JK, Fuhrman CR, et al. Quantitative computed tomography analysis, airflow obstruction, and lung cancer in the Pittsburgh lung screening study. J Thorac Oncol 2011; 6: 1200–1205.
52. 52 Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728–735.
53. 53 Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137: 1091–1097.
54. 54 Bowler RP, Kim V, Regan E, et al. Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest 2014; 146: 941–950.
55. 55 Tan WC, Bourbeau J, Hernandez P, et al. Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study. Thorax 2014; 69: 709–717.
56. 56 Marin JM, Soriano JB, Carrizo SJ, et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: The overlap syndrome. Am J Respir Crit Care Med 2010; 182: 325–331.
57. 57 Jha P, Peto R. Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med 2014; 370: 60–68.
58. 58 Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675–679.
59. 59 Parkes G, Greenhalgh T, Griffin M, et al. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008; 336: 598–600.
60. 60 Bednarek M, Gorecka D, Wielgomas J, et al. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006; 61: 869–873.
61. 61 Stratelis G, Mölstad S, Jakobsson P, et al. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scand J Prim Health Care 2006; 24: 133–139.
62. 62 Kotz D, Wesseling G, Huibers MJH, et al. Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J 2009; 33: 754–762.
63. 63 Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: A double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571–1575.
64. 64 Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: A randomized controlled trial. Chest 2011; 139: 591–599.
65. 65 Tønnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest 2006; 130: 334–342.
66. 66 Wagena EJ, van der Meer RM, Ostelo RJ, et al. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: Results from a systematic review. Respir Med 2004; 98: 805–815.
67. 67 Wilson I. Depression in the patient with COPD. Int J Chron Obstruct Pulmon Dis 2006; 1: 61–64.
68. 68 Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized trial. Circulation 2010; 121: 221–229.
69. 69 Ellerbeck EF, Mahnken JD, Cupertino AP, et al. Effect of varying levels of disease management on smoking cessation: A randomized trial. Ann Intern Med 2009; 150: 437–446.
70. 70 Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guidelines. Rockville, U.S., Department of Health and Human Services, 2008.
71. 71 Crowley TJ, Macdonald MJ, Walter MI. Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology (Berl) 1995; 119: 193–204.
72. 72 Etter J-F, Bullen C, Flouris AD, et al. Electronic nicotine delivery systems: a research agenda. Tob Control 2011; 20: 243–248.
73. 73 Etter J-F, Bullen C. Electronic cigarette: Users profile, utilization, satisfaction and perceived efficacy. Addiction 2011; 106: 2017–2028.
74. 74 Goniewicz MK, Lingas EO, Hajek P. Patterns of electronic cigarette use and user beliefs about their safety and benefits: An internet survey. Drug Alcohol Rev 2013; 32: 133–140.
75. 75 Bertholon JF, Becquemin MH, Annesi-Maesano I, et al. Electronic cigarettes: A short review. Respiration 2013; 86: 433–438.
76. 76 Schraufnagel DE, Blasi F, Drummond MB, et al. Electronic cigarettes. A position statement of the forum of international respiratory societies. Am J Respir Crit Care Med 2014; 190: 611–618.
77. 77 Buist AS, Sexton GJ, Nagy JM, et al. The effect of smoking cessation and modification on lung function. Am Rev Respir Dis 1976; 114: 115–122.
78. 78 Jiménez-Ruiz C, Solano S, Viteri SA, et al. Harm reduction – a treatment approach for resistant smokers with tobacco-related symptoms. Respiration 2002; 69: 452–455.
79. 79 Rennard SI, Daughton D, Fujita J, et al. Short-term smoking reduction is associated with reduction in measures of lower respiratory tract inflammation in heavy smokers. Eur Respir J 1990; 3: 752–759.
80. 80 Simmons MS, Connett JE, Nides MA, et al. Smoking reduction and the rate of decline in FEV1: Results from the Lung Health Study. Eur Respir J 2005; 25: 1011–1017.
81. 81 Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res 2006; 8: 739–749.
82. 82 Tetrault JM, Crothers K, Moore BA, et al. Effects of marijuana smoking on pulmonary function and respiratory complications: A systematic review. Arch Intern Med 2007; 167: 221–228.
83. 83 Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789.
84. 84 Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–1554.
85. 85 Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59.
86. 86 Burgel PR, Paillasseur JL, Dusser D, et al. Tiotropium might improve survival in subjects with COPD at high risk of mortality. Respir Res 2014; 15: 64.
87. 87 Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332–338.
88. 88 Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171–1178.
89. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9: CD009157.
90. 90 Rabe KF, Fabbri LM, Israel E, et al. Effect of ADRB2 polymorphism on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respir Med 2014; 2: 44–53.
91. 91 Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): A randomised, blinded, parallel-group study. Lancet Respir Med 2013; 1: 524–533.
92. 92 Calverley PM, Stockley RA, Seemungal TA, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011; 139: 505–512.
93. 93 Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34: 641–647.
94. 94 Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19–26.
95. 95 Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 2007; 146: 545–555.
96. 96 Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199–209.
97. 97 Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371: 1285–1294.
98. 98 Price LC, Lowe D, Hosker HS, et al. UK National COPD Audit 2003: Impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation. Thorax 2006; 61: 837–842.
99. 99 Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880–887.
100. 100 Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest 2011; 139: 165–173.
101. 101 Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: Key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13–e64.
102. 102 Vieira DS, Maltais F, Bourbeau J. Home-based pulmonary rehabilitation in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2010; 16: 134–143.
103. 103 Maltais F, Bourbeau J, Shapiro S, et al. Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 2008; 149: 869–878.
104. 104 van Wetering CR, Hoogendoorn M, Mol SJ, et al. Short- and long-term efficacy of a community-based COPD management programme in less advanced COPD: A randomised controlled trial. Thorax 2010; 65: 7–13.
105. 105 van Wetering CR, Hoogendoorn M, Broekhuizen R, et al. Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: A prespecified subgroup analysis of the INTERCOM trial. J Am Med Dir Assoc 2010; 11: 179–187.
106. Puhan MA, Gimeno-Santos E, Scharplatz M, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; 10: CD005305.
107. 107 Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809–817.
108. 108 Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681–686.
109. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93: 391–398.
110. 110 Górecka D, Gorzelak K, Sliwiński P, et al. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 1997; 52: 674–679.
111. 111 Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333: 817–822.
112. 112 Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993; 341: 1555–1557.
113. 113 Kramer N, Meyer TJ, Meharg J, et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995; 151: 1799–1806.
114. 114 Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: A multicentre randomised controlled trial. Lancet 2000; 355: 1931–1935.
115. 115 Nava S, Hill N. Non-invasive ventilation in acute respiratory failure. Lancet 2009; 374: 250–259.
116. 116 Bhatt SP, Peterson MW, Wilson JS, et al. Noninvasive positive pressure ventilation in subjects with stable COPD: A randomized trial. Int J Chron Obstruct Pulmon Dis 2013; 8: 581–589.
117. 117 Lamia B, Cuvelier A, Benichou J, et al. Bénéfices de la ventilation non invasive a domicile au décours d’une insuffisance respiratoire aigue hypercapnique chez les patients BPCO. Etude contrôlée randomisée multicentrique. Etude Non Invasive Ventilation in Obstructive Lung Disease (Nivold) [A multi-centre randomized controlled trial of domiciliary non-invasive ventilation vs long-term oxygen therapy in survivors of acute hypercapnic respiratory failure due to COPD. Non-invasive ventilation in obstructive lung disease (NIVOLD) study]. Rev Mal Respir 2012; 29: 1141–1148.
118. 118 Clini E, Sturani C, Rossi A, et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 2002; 20: 529–538.
119. 119 Struik FM, Sprooten RT, Kerstjen HA, et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: A randomized, controlled, parallel-group study. Thorax 2014; 69: 826–834.
120. 120 Struik FM, Lacasse Y, Goldstein RS, et al. Nocturnal noninvasive positive pressure ventilation in stable COPD: a systematic review and individual patient data meta-analysis. Respir Med 2014; 108: 329–337.
121. 121 Kohnlein T, Windisch W, Kohler D, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: A prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med 2014; 2: 698–705.